Wedbush Cuts Price Target on Apellis Pharmaceuticals to $35 From $41, Maintains Neutral Rating; Shares Fall
Wedbush Cuts Price Target on Apellis Pharmaceuticals to $35 From $41, Maintains Neutral Rating; Shares Fall
Wedbush将Apellis Pharmaceuticals的目标股价从41美元下调至35美元,维持中立评级;股价下跌
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册